Could a common pill stop kidney failure in ICU?
NCT ID NCT05468203
Summary
This study aimed to see if giving the drug dapagliflozin to patients in intensive care could prevent severe kidney injury. It planned to enroll 3,000 critically ill adults at high risk for kidney problems from hospitals worldwide. Patients were randomly assigned to receive either the active drug or a placebo pill daily for up to 30 days while in the ICU.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Epworth Richmond
Richmond, Victoria, 3121, Australia
-
Grampians Health
Ballarat, Victoria, 3350, Australia
Conditions
Explore the condition pages connected to this study.